Morphine / cyclizine : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00010549/202210

List of eligible industry stakeholder organisations

morphine / cyclizine : List of nationally authorised medicinal products - PSUSA/00010549/202210

Human medicines European public assessment report (EPAR): Vpriv, velaglucerase alfa, Gaucher Disease, Date of authorisation: 26/08/2010, Revision: 20, Status: Authorised

Orphan designation: Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase (Bevufenogene nofeparvovec), Treatment of mucopolysaccharidosis type II (Hunter Syndrome), 16/03/2022, Withdrawn

Orphan designation: Adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase, Treatment of phenylalanine hydroxylase deficiency, 14/12/2018, Withdrawn

Orphan designation: Human telomerase reverse transcriptase peptide (611-626) (tertomotide), Treatment of pancreatic cancer, 25/07/2006, Withdrawn

Document file name in title field

Withdrawn application: Lumevoq, lenadogene nolparvovec, Date of withdrawal: 20/04/2023, Initial authorisation